



## ALZHEIMER'S DISEASE Patient and Caregiver Engagement Initiative




AD PACE is a patient and caregiver-led collaboration of industry, government agencies and patient advocates that is building a standing, longitudinal platform to deliver to regulators, payers and industry, needed insights into the preferences of those at risk for or living with Alzheimer's and their caregivers.

### AD PACE ASSETS



#### NEW KNOWLEDGE

- What Matters qualitative research
- What Matters Most quantitative research
- Knowledge landscape
- Gap analysis
- Informing FDA PFDD policy and guidance development



#### THE A-LIST

- 6,000+ individuals and growing
- Ready and willing to participate in preference research
- Potential for longitudinal analysis
- Creating an Alzheimer's lexicon



#### DATA COMMONS

- Searchable de-identified data
- Collection of insights and preference data
- Mining and analysis
- Generated from AD PACE projects and acquired from sponsors and partnerships



#### AD PACE TOOLKIT

- Re-purposed tools
- New tool development
- Clinical outcome assessments
- Tool validation
- For use as endpoints

For more information on sponsoring or partnership opportunities, please visit the AD PACE website at [www.usagainstalzhimers.org/ad-pace](http://www.usagainstalzhimers.org/ad-pace).



## ALZHEIMER'S DISEASE Patient and Caregiver Engagement Initiative

Determining what matters most to Alzheimer's patients and caregivers to inform treatment outcomes, regulatory reviews and payer decisions

AD PACE is a patient and caregiver-led collaboration of industry, academics, government agencies and advocates, building a standing platform to determine a scientifically rigorous understanding of Alzheimer's patient insights to inform drug development regulators and payers.

### INITIATIVE TIMELINE (4.5 YEARS)

NOVEMBER 2017

#### PHASE 0

Design phase, completed 4/2017

#### PHASE 1

What Matters and What Matters Most research, Data Commons development and build out of the A-LIST

MAY 2022

#### PHASE 2

Gap analysis and tool development plan

#### PHASE 3

Expanded and parallel uses of AD PACE assets

### AD PACE IMPACT



Bringing the voice of those at risk for and affected by Alzheimer's into the drug development process.



Making sure that new therapies impact outcomes that matter to patients



Using patient experience data to inform the regulatory approval process, payment and reimbursement decisions, and care and services.